

6 September 2010

AquaBounty Technologies, Inc.
(“AquaBounty” or “the Company”)

**Availability of the Briefing Documentation for the VMAC Meeting to Consider
AquAdvantage[®] Salmon**

AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, notes that, following the announcement on 25 August 2010 by the US Food and Drug Administration of the proposed meeting later this month of the Veterinary Medicine Advisory Committee (the “Committee”), the Committee has now posted the briefing materials for the meeting. These materials can be viewed at: www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/VeterinaryMedicineAdvisoryCommittee/ucm201810.htm

The Company explained in its previous announcement on 25 August 2010 that the Committee will review and evaluate available data concerning the safety and effectiveness of the product in question and make appropriate recommendations to the FDA. The FDA will make a decision on approval following these recommendations.

For further information, please contact:

AquaBounty Technologies David Frank, Chief Financial Officer	+1 781 899 7755
Nomura Code Securities Richard Potts, Giles Balleny	+44 (0)20 7776 1200
Corfin Public Relations Harry Chathli, Claire Norbury, Neil Thapar	+44 (0)20 7596 2860